FAQ
Written for patients seeking information, scientists, clinicians, and investors. PHP53-nb is investigational and is not medical advice.
PHP Biotech International Inc. is a US-based, privately held biotechnology company founded in 2020 and headquartered in Southlake, Texas. It develops intracellular nanobody therapeutics designed to restore p53 apoptotic function in aggressive solid tumors, starting with triple-negative breast cancer.
PHP53-nb is PHP Biotech’s lead candidate: a first-in-class humanized camelid nanobody that genetically incorporates the p53-reactivating peptide 3-NAntC. It is engineered to enter tumor cells, reactivate mutant p53, and trigger apoptosis. It is investigational and not approved by the FDA.
PHP53-nb binds a tumor-associated membrane ligand, enters the cell by endocytosis, and releases its payload in the cytoplasm. That payload drives oxidative and ER stress, reactivates p53 signaling, collapses mitochondria, and commits the cancer cell to programmed death.
A nanobody is a single-domain antibody fragment derived from camelid heavy-chain antibodies. At about 17 kDa, PHP53-nb is roughly one-tenth the size of a traditional monoclonal antibody (~150 kDa), which can improve tumor penetration, stability, and manufacturing economics.
p53 is a tumor-suppressor protein often called the guardian of the genome. Mutations in TP53, the gene that encodes p53, occur in about half of all human cancers and in a still higher share of aggressive tumors. Restoring p53 function is a long-sought, historically difficult oncology strategy.
Preclinical work focuses on triple-negative breast cancer, with additional activity reported in ovarian and pancreatic tumor models and other TP53-mutant lines. Selectivity versus wild-type p53 benign control cells is a central claim of the data package.
GEN01-AD is PHP Biotech’s proprietary humanized camelid nanobody scaffold, built to deliver unstable therapeutic peptides into tumor cells. The 3-NAntC peptide is genetically integrated into the nanobody itself — no chemical linkers — and the same architecture can carry other payloads.
No. As of 2026 the program is preclinical. PHP Biotech has described planned completion of preclinical studies in 2026 and an anticipated start of Phase I clinical trials in 2027, subject to regulatory review. Preclinical results do not guarantee clinical benefit.
No. PHP53-nb is an investigational biologic. It has not been approved by the U.S. Food and Drug Administration or any other regulatory authority, and it is not available as a treatment outside authorized clinical research.
PHP53-nb is expressed in CHO cells using standard bioprocessing. Gene-optimized plasmids increased yields more than 100-fold versus early lab scale, from about 5 mg/L to 693 mg/L, with further gains expected from cell-line and process development.
PHP Biotech is headquartered at 550 Reserve Street, Suite 190, Southlake, Texas 76092, in the Dallas–Fort Worth area. The company works with a global network of CROs and CDMOs specializing in nanobody and translational biotechnology.
Use the contact form on this site or email contact@phpbiotech.com. The team welcomes scientific collaborators, CRO/CDMO partners, and qualified investors interested in first-in-class intracellular biologics.